

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**


**1. (withdrawn-previously presented):** A method for treatment and/or prevention of a disease due to constriction or vasodilation of blood vessels, which comprises administering to a mammal an effective dose of the compound according to claim 10.

**2. (withdrawn-previously presented):** The method according to claim 1, wherein the disease due to constriction or vasodilation of blood vessels is selected from cerebrovascular spasmodic disorder, cardiovascular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure, varicosity, chronic headache, haemorrhoid and congestive disorder.

**3. (withdrawn- previously presented):** The method according to claim 2, wherein the blood vessel is a cerebral artery, a renal artery, a coronary artery, a pulmonary artery, an aorta or a vein.


**4-9. (canceled).**

**10. (currently amended):** A compound represented by formula (I):



wherein:

A represents



wherein R<sup>1</sup> represents a substituent,

R<sup>2</sup> represents hydroxy or C1-6 alkoxy,

R<sup>3</sup> represents a substituent, and

r represents 0 or an integer of 1-4,

X represents a single bond,

Y represents -CO-,

Z represents a nitrogen atom optionally substituted with C1-6 alkoxy,

B represents ~~a cyclic group~~ an aromatic ring optionally with ~~a 1-5~~ substituent(s) selected from (1)  
alkenyl optionally with a substituent(s), (2) alkynyl optionally with a substituent(s), (3)  
carbocyclic ring optionally with a substituent(s), (4) heterocyclic ring optionally with a  
substituent(s), (5) hydroxyl optionally with a substituent(s), (6) thiol optionally with a  
substituent(s), (7) amino optionally with a substituent(s), (8) carbamoyl optionally with a  
substituent(s), (9) sulfamoyl optionally with a substituent(s), (10) carboxyl, (11) alkoxycarbonyl,  
(12) sulfo, (13) sulfinio, (14) phosphono, (15) nitro, (16) cyano, (17) amidino, (18) imino, (19)  
-B(OH)<sub>2</sub>, (20) halogen atom, (21) alkylsulfinyl, (22) aromatic ring sulfinyl, (23) alkylsulfonyl,  
(24) aromatic ring sulfonyl, (25) acyl, (26) oxo, (27) thioxo, and (28) (C1-6 alkoxyimino)  
methyl, or a pharmaceutically acceptable salt thereof.

**11-19. (canceled).**

**20. (previously presented):** The compound according to claim 10, wherein R<sup>2</sup> is hydroxy.

**21. (canceled).**

**22. (original):** The compound according to claim 20, wherein R<sup>1</sup> is a chain substituent.

**23. (canceled).**


24. (original): The compound according to claim 22, wherein the chain substituent is alkyl.

25. (original): The compound according to claim 22, wherein the chain substituent is substituted alkyl.

26-28. (canceled).

29. (currently amended): The compound according to claim 27, wherein the ~~eyelet~~ aromatic group-ring is substituted with 1 or at least 2 substituent(s) selected from (1) alkenyl optionally with a substituent(s), (2) alkynyl optionally with a substituent(s), (3) carbocyclic ring optionally with a substituent(s), (4) heterocyclic ring optionally with a substituent(s), (5) hydroxyl optionally with a substituent(s), (6) thiol optionally with a substituent(s), (7) amino optionally with a substituent(s), (8) carbamoyl optionally with a substituent(s), (9) sulfamoyl optionally with a substituent(s), (10) carboxyl, (11) alkoxy carbonyl, (12) sulfo, (13) sulfinio, (14) phosphono, (15) nitro, (16) cyano, (17) amidino, (18) imino, (19) -B(OH)<sub>2</sub>, (20) halogen atom, (21) alkylsulfinyl, (22) aromatic ring sulfinyl, (23) alkylsulfonyl, (24) aromatic ring sulfonyl, (25) acyl, (26) oxo, (27) thioxo, and (28) (C1-6 alkoxyimino) methyl.

30. (currently amended): The compound according to claim 29, wherein the ~~eyelet~~ aromatic group-ring with at least 2 substituents is



wherein B<sup>1</sup> represents a carbon ring of an aromatic ring,

R<sup>11</sup> and R<sup>12</sup> each represents a substituent selected from (1) alkenyl optionally with a substituent(s), (2) alkynyl optionally with a substituent(s), (3) carbocyclic ring optionally with a

substituent(s), (4) heterocyclic ring optionally with a substituent(s), (5) hydroxyl optionally with a substituent(s), (6) thiol optionally with a substituent(s), (7) amino optionally with a substituent(s), (8) carbamoyl optionally with a substituent(s), (9) sulfamoyl optionally with a substituent(s), (10) carboxyl, (11) alkoxycarbonyl, (12) sulfo, (13) sulfino, (14) phosphono, (15) nitro, (16) cyano, (17) amidino, (18) imino, (19) -B(OH)<sub>2</sub>, (20) halogen atom, (21) alkylsulfanyl, (22) aromatic ring sulfanyl, (23) alkylsulfanyl, (24) aromatic ring sulfonyl, (25) acyl, (26) oxo, (27) thiooxo, and (28) (C1-6 alkoxyimino) methyl.


m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.

**31-45. (canceled).**

**46. (currently amended):** The compound according to claim [[44]]10, wherein the eyelie-aromatic group-ring is substituted with 1 or at least 2 substituent(s) selected from (1) alkenyl optionally with a substituent(s), (2) alkynyl optionally with a substituent(s), (3) carbocyclic ring optionally with a substituent(s), (4) heterocyclic ring optionally with a substituent(s), (5) hydroxyl optionally with a substituent(s), (6) thiol optionally with a substituent(s), (7) amino optionally with a substituent(s), (8) carbamoyl optionally with a substituent(s), (9) sulfamoyl optionally with a substituent(s), (10) carboxyl, (11) alkoxycarbonyl, (12) sulfo, (13) sulfino, (14) phosphono, (15) nitro, (16) cyano, (17) amidino, (18) imino, (19) -B(OH)<sub>2</sub>, (20) halogen atom, (21) alkylsulfanyl, (22) aromatic ring sulfanyl, (23) alkylsulfonyl, (24) aromatic ring sulfonyl, (25) acyl, (26) oxo, (27) thiooxo, and (28) (C1-6 alkoxyimino) methyl.

**47. (currently amended):** The compound according to claim 46, wherein the eyelie aromatic group-ring with at least 2 substituents is



wherein B¹ represents a carbon ring of an aromatic ring,

R¹¹ and R¹² each represents a substituent selected from (1) alkenyl optionally with a substituent(s), (2) alkynyl optionally with a substituent(s), (3) carbocyclic ring optionally with a substituent(s), (4) heterocyclic ring optionally with a substituent(s), (5) hydroxyl optionally with a substituent(s), (6) thiol optionally with a substituent(s), (7) amino optionally with a substituent(s), (8) carbamoyl optionally with a substituent(s), (9) sulfamoyl optionally with a substituent(s), (10) carboxyl, (11) alkoxy carbonyl, (12) sulfo, (13) sulfino, (14) phosphono, (15) nitro, (16) cyano, (17) amidino, (18) imino, (19) -B(OH)₂, (20) halogen atom, (21) alkylsulfinyl, (22) aromatic ring sulfinyl, (23) alkylsulfonyl, (24) aromatic ring sulfonyl, (25) acyl, (26) oxo, (27) thioxo, and (28) (C1-6 alkoxyimino) methyl

m represents an integer of 1-4, and


the other symbols have the same meanings as those mentioned above.

**48-50. (canceled).**

**51. (currently amended):** The compound according to claim 4925, wherein the eyelid aromatic group ring is substituted with 1 or at least 2 substituents selected from (1) alkenyl optionally with a substituent(s), (2) alkynyl optionally with a substituent(s), (3) carbocyclic ring optionally with a substituent(s), (4) heterocyclic ring optionally with a substituent(s), (5) hydroxyl optionally with a substituent(s), (6) thiol optionally with a substituent(s), (7) amino optionally with a substituent(s), (8) carbamoyl optionally with a substituent(s), (9) sulfamoyl optionally with a substituent(s), (10) carboxyl, (11) alkoxy carbonyl, (12) sulfo, (13) sulfino, (14)

phosphono, (15) nitro, (16) cyano, (17) amidino, (18) imino, (19) -B(OH)<sub>2</sub>, (20) halogen atom, (21) alkylsulfinyl, (22) aromatic ring sulfinyl, (23) alkylsulfonyl, (24) aromatic ring sulfonyl, (25) acyl, (26) oxo, (27) thioxo, and (28) (C1-6 alkoxyimino) methyl.

**52. (currently amended):** The compound according to claim 51, wherein the cyclic group with at least 2 substituents is



wherein B<sup>1</sup> represents a carbon ring of an aromatic ring,

R<sup>11</sup> and R<sup>12</sup> each represents a substituents selected from (1) alkenyl optionally with a substituent(s), (2) alkynyl optionally with a substituent(s), (3) carbocyclic ring optionally with a substituent(s), (4) heterocyclic ring optionally with a substituent(s), (5) hydroxyl optionally with a substituent(s), (6) thiol optionally with a substituent(s), (7) amino optionally with a substituent(s), (8) carbamoyl optionally with a substituent(s), (9) sulfamoyl optionally with a substituent(s), (10) carboxyl, (11) alkoxycarbonyl, (12) sulfo, (13) sulfinio, (14) phosphono, (15) nitro, (16) cyano, (17) amidino, (18) imino, (19) -B(OH)<sub>2</sub>, (20) halogen atom, (21) alkylsulfinyl, (22) aromatic ring sulfinyl, (23) alkylsulfonyl, (24) aromatic ring sulfonyl, (25) acyl, (26) oxo, (27) thioxo, and (28) (C1-6 alkoxyimino) methyl.

m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.

**53-60. (canceled).**

**61. (withdrawn-previously presented):** A method for treatment and/or prevention of a disease due to constriction of blood vessels in a mammal, which comprises administering to a

mammal an effective dose of the compound according to claim 10 or a pharmaceutically salt acceptable thereof.

**62. (withdrawn-previously presented):** A method for inhibition of EDG-5 in a mammal, which comprises administering to a mammal an effective dose of the compound according to claim 10 or a pharmaceutically acceptable salt thereof.

**63-70. (canceled).**